Watchdog recommends Price subpoena in stock sales probe

Watchdog recommends Price subpoena in stock sales probe
© Getty Images

A congressional watchdog is recommending the subpoena of former Health and Human Services Secretary Tom PriceThomas (Tom) Edmunds PriceOvernight Health Care — Presented by Partnership for America's Health Care Future — Warren faces tough choices on 'Medicare for All' funding | Dems demand answers on Tom Price's charter flights | Medicaid expansion nears 2020 ballot in Oklahoma Senate Democrats demand answers on payment for Tom Price's charter flights Industrial food system is at the heart of biodiversity degradation and climate change MORE after he refused to cooperate in its probe of Rep. Chris CollinsChristopher (Chris) Carl CollinsOn The Money: Economy adds 136K jobs in September | Jobless rate at 50-year low | Treasury IG to probe handling of Trump tax returns request | House presses Zuckerberg to testify on digital currency Two Collins associates plead guilty in insider trading case On The Money: Trump blames Fed as manufacturing falters | US to join Trump lawsuit over NY subpoena for tax returns | Ex-Rep. Chris Collins pleads guilty in insider trading case MORE (R-N.Y.) related to stock sales of an Australian biotechnology firm.

The Office of Congressional Ethics (OCE) on Thursday said Price was one of 10 individuals or entities that refused to cooperate with the investigation into whether Collins improperly shared nonpublic information in the purchase of Innate Immunotherapeutics Limited stocks.

Collins sits on Innate’s board and is the company’s largest shareholder.

In its report, the watchdog said there is "substantial reason to believe" Collins violated federal law and House rules, recommending the House Ethics Committee probe the claims.

OCE, an independent entity that reviews allegations against House members, also advised issuing a subpoena for Price to determine what he knew about the stocks.

Innate said it sold nearly $1 million in stock in discounted shares to Price while he was still a congressman, according to a Wall Street Journal report.


Price came under fire during his confirmation hearings for stock trades made while he was involved in health-care legislation as a member of Congress.

Price defended his stock trades in the hearings and denied wrongdoing.

Democrats said he could have broken insider trading laws or a law against trading on congressional knowledge.

Price sold his shares of Innate in February, earning at least $225,000 on a $94,000 investment, according to congressional disclosure forms. The sales were made to comply with the ethics agreement he signed when he became the Health secretary.

Price resigned as Health secretary late last month after intense criticism of his use of private jets for professional trips at taxpayer expense, reportedly racking up more than $1 million in flights in just eight months.